First and solely subcutaneous anti-CD38 remedy demonstrating potential to stop end-organ harm, and prolong progression-free survival and total survival based mostly on findings from Part 3 AQUILA examine

SAN DIEGO, Dec. 8, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) at the moment introduced information from the Part 3 AQUILA examine exhibiting that DARZALEX FASPRO ^® (daratumumab and hyaluronidase-fihj) considerably delayed development from high-risk smoldering a number of myeloma (SMM) to energetic a number of myeloma (MM) and prolonged total survival in comparison with the present customary of care of energetic monitoring.¹ The information had been offered for the primary time as an oral presentation on the 2024 American Society of Hematology (ASH) Annual Assembly (Summary #773), as a part of the Press Program and had been chosen for the Better of ASH session.

Within the AQUILA examine, 194 sufferers obtained DARZALEX FASPRO ^® and 196 sufferers had been actively monitored per present customary of care therapy for high-risk SMM. At a median follow-up of 65.2 (vary, 0-76.6) months, sufferers who obtained DARZALEX FASPRO ^® confirmed statistically important improved progression-free survival (PFS; outlined as development to energetic MM as assessed in keeping with Worldwide Myeloma working Group (IMWG) diagnostic standards for MM [SLiM-CRAB] or dying) than the energetic monitoring group; 63.1 % versus 40.8 % of sufferers remained progression-free at 60 months (hazard ratio [HR], 0.49; 95 % confidence interval [CI], 0.36-0.67; PFASPRO ^® arm and was 22.1 months within the energetic monitoring arm (HR, 0.36; 95 % CI, 0.23-0.58). Total survival was additionally prolonged with DARZALEX FASPRO ^®, with 5-year survival charges of 93 % versus 86.9 % for energetic monitoring (HR, 0.52; 95 % CI, 0.27-0.98).¹

“Patients with high-risk smoldering multiple myeloma, which has no approved treatment, have a high probability of progressing to active multiple myeloma “ a life-threatening stage of the disease,” mentioned Meletios A. Dimopoulos, M.D., Professor and Chairman of the Division of Medical Therapeutics on the Nationwide and Kapodistrian College of Athens Faculty of Medication and presenting writer. “Findings from AQUILA highlight the potential of early intervention with DARZALEX FASPRO to delay disease progression, extend overall survival and prevent end-organ damage associated with active multiple myeloma.”

Moreover, sufferers who obtained DARZALEX FASPRO ^® noticed a better total response charge of 63.4 % in comparison with 2.0 % with energetic monitoring (P FASPRO ^® in comparison with 50.2 months with energetic monitoring (HR, 0.46; 95 % CI, 0.33-0.62; nominal P1

“We are encouraged by the findings from the AQUILA study, which may help to underscore the critical role of early disease intervention and potential to improve outcomes for patients with high-risk smoldering multiple myeloma,” mentioned Jordan Schecter, M.D., Vice President, Illness Space Chief, A number of Myeloma, Johnson & Johnson Progressive Medication. “This proactive approach further highlights our goal of evolving the standard of care for patients at every stage of the disease.”

Grade 3/4 treatment-emergent hostile occasions (TEAEs) occurred in 40.4 % of sufferers handled with DARZALEX FASPRO ^® and 30.1 % of sufferers actively monitored. The most typical ( ‰¥5 % in both group) Grade 3/4 TEAE was hypertension (5.7 % vs.4.6 %, respectively). The frequency of TEAEs resulting in discontinuation of DARAZLEX FASPRO ^® was low (5.7 %), as was the incidence of deadly TEAEs in each teams (0.5 % vs. 2.0 %, respectively).¹

Final month, Johnson & Johnson submitted a supplemental Biologics License Software to the U.S. Meals and Drug Administration and an Extension of Indication software to the European Medicines Company for DARZALEX FASPRO ^® and DARZALEX ^® subcutaneous (SC) formulation, respectively, for the therapy of grownup sufferers with high-risk SMM based mostly on the Part 3 AQUILA information.

In regards to the AQUILA Examine
AQUILA (NCT03301220) is a randomized, multicenter Part 3 examine evaluating therapy with DARZALEX FASPRO ^® to energetic monitoring in sufferers with smoldering a number of myeloma. The first endpoint is progression-free survival (PFS), outlined as development to energetic a number of myeloma as assessed by an impartial overview committee and in keeping with IMWG diagnostic standards for MM (SLiM-CRAB) or dying. Main secondary endpoints included total response charge, PFS on first-line MM therapy (PFS2), and total survival.

About Smoldering A number of Myeloma
Smoldering a number of myeloma (SMM) is an asymptomatic precursor state to a number of myeloma (MM). Sufferers with SMM have greater ranges of irregular plasma cells within the bone marrow and an elevated monoclonal protein (M-protein) stage within the blood, however they don’t but exhibit the signs generally related to energetic a number of myeloma, notably end-organ harm. Fifteen % of all instances of newly identified a number of myeloma are labeled as SMM, and half of these identified with high-risk illness will progress to energetic a number of myeloma inside two years.²

About A number of Myeloma
A number of myeloma is a blood most cancers that impacts a sort of white blood cell known as plasma cells, that are discovered within the bone marrow.² In a number of myeloma, these malignant plasma cells proliferate and exchange regular cells within the bone marrow.³ A number of myeloma is the second most typical blood most cancers worldwide and stays an incurable illness.⁴ In 2024, it’s estimated that greater than 35,000 individuals will probably be identified with a number of myeloma within the U.S. and greater than 12,000 will die from the illness.⁵ Individuals with a number of myeloma have a 5-year survival charge of 59.8 %. Whereas some individuals identified with a number of myeloma initially haven’t any signs, most sufferers are identified resulting from signs that may embody bone fracture or ache, low purple blood cell counts, tiredness, excessive calcium ranges, kidney issues or infections.^6,7

About DARZALEX FASPRO ^® and DARZALEX ^®

DARZALEX FASPRO ^® (daratumumab and hyaluronidase-fihj) obtained U.S. FDA approval in Might 2020 and is authorized for 9 indications in a number of myeloma, 4 of that are for frontline therapy in newly identified sufferers who’re transplant eligible or ineligible.^1,4 It’s the solely subcutaneous CD38-directed antibody authorized to deal with sufferers with MM. DARZALEX FASPRO ^® is co-formulated with recombinant human hyaluronidase PH20, Halozyme (NASDAQ:)’s ENHANZE ^® drug supply expertise.

DARZALEX ^® (daratumumab) obtained U.S. FDA approval in November 2015 and is authorized in eight indications, three of that are within the frontline setting, together with newly identified sufferers who’re transplant eligible and ineligible.⁶

DARZALEX ^® is the primary CD38-directed antibody authorized to deal with a number of myeloma.⁶ DARZALEX ^®-based regimens have been used within the therapy of greater than 585,000 sufferers worldwide and greater than 239,000 sufferers within the U.S. alone.

In August 2012, Janssen Biotech, Inc. and Genmab (NASDAQ:) A/S entered a worldwide settlement, which granted Janssen an unique license to develop, manufacture and commercialize daratumumab.

For extra info, go to https://www.darzalexhcp.com.

DARZALEX FASPRO ^® INDICATIONS AND IMPORTANT SAFETY INFORMATION¯

INDICATIONS
DARZALEX FASPRO ^® (daratumumab and hyaluronidase-fihj) is indicated for the therapy of grownup sufferers with a number of myeloma:

• Together with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly identified sufferers who’re eligible for autologous stem cell transplant
• Together with bortezomib, melphalan, and prednisone in newly identified sufferers who’re ineligible for autologous stem cell transplant
• Together with lenalidomide and dexamethasone in newly identified sufferers who’re ineligible for autologous stem cell transplant and in sufferers with relapsed or refractory a number of myeloma who’ve obtained at the least one prior remedy
• Together with bortezomib, thalidomide, and dexamethasone in newly identified sufferers who’re eligible for autologous stem cell transplant
• Together with pomalidomide and dexamethasone in sufferers who’ve obtained at the least one prior line of remedy together with lenalidomide and a proteasome inhibitor (PI)
• Together with carfilzomib and dexamethasone in sufferers with relapsed or refractory a number of myeloma who’ve obtained one to a few prior strains of remedy
• Together with bortezomib and dexamethasone in sufferers who’ve obtained at the least one prior remedy
• As monotherapy in sufferers who’ve obtained at the least three prior strains of remedy together with a PI and an immunomodulatory agent or who’re double refractory to a PI and an immunomodulatory agent

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS¯¯
DARZALEX FASPRO ^® is contraindicated in sufferers with a historical past of extreme hypersensitivity to daratumumab, hyaluronidase, or any of the parts of the formulation.¯¯

WARNINGS AND PRECAUTIONS¯¯

Hypersensitivity and Different Administration Reactions¯¯
Each systemic administration-related reactions, together with extreme or life-threatening reactions, and native injection-site reactions can happen with DARZALEX FASPRO ^®. Deadly reactions have been reported with daratumumab-containing merchandise, together with DARZALEX FASPRO ^®.

Systemic Reactions¯¯
In a pooled security inhabitants of 1249 sufferers with a number of myeloma (N=1056) or mild chain (AL) amyloidosis (N=193) who obtained DARZALEX FASPRO ® as monotherapy or together, 7% of sufferers skilled a systemic administration-related response (Grade 2: 3.2%, Grade 3: 0.7%, Grade 4: 0.1%). Systemic administration-related reactions occurred in 7% of sufferers with the primary injection, 0.2% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 2.9 hours (vary: 5 minutes to three.5 days). Of the 165 systemic administration-related reactions that occurred in 93 sufferers, 144 (87%) occurred on the day of DARZALEX FASPRO ^® administration. Delayed systemic administration-related reactions have occurred in 1% of the sufferers.

Extreme reactions included hypoxia, dyspnea, hypertension, tachycardia, and ocular hostile reactions, together with choroidal effusion, acute myopia, and acute angle closure glaucoma. Different indicators and signs of systemic administration-related reactions might embody respiratory signs, similar to bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, in addition to anaphylactic response, pyrexia, chest ache, pruritus, chills, vomiting, nausea, hypotension, and blurred imaginative and prescient.¯¯

Pre-medicate sufferers with histamine-1 receptor antagonist, acetaminophen, and corticosteroids. Monitor sufferers for systemic administration-related reactions, particularly following the primary and second injections. For anaphylactic response or life-threatening (Grade 4) administration-related reactions, instantly and completely discontinue DARZALEX FASPRO ^®. Contemplate administering corticosteroids and different medicines after the administration of DARZALEX FASPRO ^® relying on dosing routine and medical historical past to attenuate the danger of delayed (outlined as occurring the day after administration) systemic administration-related reactions.¯¯

Ocular hostile reactions, together with acute myopia and narrowing of the anterior chamber angle resulting from ciliochoroidal effusions with potential for elevated intraocular stress or glaucoma, have occurred with daratumumab-containing merchandise. If ocular signs happen, interrupt DARZALEX FASPRO ^® and search rapid ophthalmologic analysis previous to restarting DARZALEX FASPRO ^®.¯¯

Native Reactions¯¯

On this pooled security inhabitants, injection-site reactions occurred in 7% of sufferers, together with Grade 2 reactions in 0.8%. Essentially the most frequent (>1%) injection-site response was injection-site erythema. These native reactions occurred a median of 5 minutes (vary: 0 minutes to six.5 days) after beginning administration of DARZALEX FASPRO ^®. Monitor for native reactions and contemplate symptomatic administration. ¯

Neutropenia¯¯
Daratumumab might enhance neutropenia induced by background remedy. Monitor full blood cell counts periodically throughout therapy in keeping with producer’s prescribing info for background therapies. Monitor sufferers with neutropenia for indicators of an infection. Contemplate withholding DARZALEX FASPRO ^® till restoration of neutrophils. In decrease physique weight sufferers receiving DARZALEX FASPRO ^®, greater charges of Grade 3-4 neutropenia had been noticed.¯¯

Thrombocytopenia¯¯
Daratumumab might enhance thrombocytopenia induced by background remedy. Monitor full blood cell counts periodically throughout therapy in keeping with producer’s prescribing info for background therapies. Contemplate withholding DARZALEX FASPRO ^® till restoration of platelets.¯¯

Embryo-Fetal Toxicity¯¯
Primarily based on the mechanism of motion, DARZALEX FASPRO ^® could cause fetal hurt when administered to a pregnant lady. DARZALEX FASPRO ^® might trigger depletion of fetal immune cells and decreased bone density. Advise pregnant ladies of the potential threat to a fetus. Advise females with reproductive potential to make use of efficient contraception throughout therapy with DARZALEX FASPRO ^® and for 3¯months after the final dose.¯¯

The mix of DARZALEX FASPRO ^® with lenalidomide, thalidomide, or pomalidomide is contraindicated in pregnant ladies as a result of lenalidomide, thalidomide, and pomalidomide might trigger start defects and dying of the unborn little one. Confer with the lenalidomide, thalidomide, or pomalidomide prescribing info on use throughout being pregnant.¯¯

Interference With Serological Testing¯¯
Daratumumab binds to CD38 on purple blood cells (RBCs) and leads to a constructive oblique antiglobulin check (oblique Coombs check). Daratumumab-mediated constructive oblique antiglobulin check might persist for up to six¯months after the final daratumumab administration. Daratumumab certain to RBCs masks detection of antibodies to minor antigens within the affected person’s serum. The willpower of a affected person’s ABO and Rh blood kind usually are not impacted.¯¯

Notify blood transfusion facilities of this interference with serological testing and inform blood banks {that a} affected person has obtained DARZALEX FASPRO ^®. Kind and display sufferers previous to beginning DARZALEX FASPRO ^®.¯¯

Interference With Dedication of Full Response¯¯
Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that may be detected on each the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the medical monitoring of endogenous M-protein. This interference can impression the willpower of full response and of illness development in some DARZALEX FASPRO ^®-treated sufferers with IgG kappa myeloma protein.¯¯

ADVERSE REACTIONS¯¯

In a number of myeloma, the most typical hostile response ( ‰¥20%) with DARZALEX FASPRO ^® monotherapy is higher respiratory tract an infection.¯The most typical hostile reactions with mixture remedy ( ‰¥20% for any mixture) embody fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, again ache, vomiting, hypertension, higher respiratory tract an infection, peripheral sensory neuropathy, constipation, pneumonia, and peripheral edema.¯¯

The most typical hematology laboratory abnormalities ( ‰¥40%) with DARZALEX FASPRO ^® are decreased leukocytes, decreased lymphocytes, decreased neutrophils, decreased platelets, and decreased hemoglobin.¯¯

Please click on right here to see the complete Prescribing Data for DARZALEX FASPRO ^®.

DARZALEX ^®¯INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

DARZALEX ^®¯(daratumumab) is indicated for the therapy of grownup sufferers with a number of myeloma:

• Together with bortezomib, melphalan, and prednisone in newly identified sufferers who’re ineligible for autologous stem cell transplant
• Together with lenalidomide and dexamethasone in newly identified sufferers who’re ineligible for autologous stem cell transplant and in sufferers with relapsed or refractory a number of myeloma who’ve obtained at the least one prior remedy
• Together with bortezomib, thalidomide, and dexamethasone in newly identified sufferers who’re eligible for autologous stem cell transplant
• Together with pomalidomide and dexamethasone in sufferers who’ve obtained at the least one prior line of remedy together with lenalidomide and a proteasome inhibitor
• Together with carfilzomib and dexamethasone in sufferers with relapsed or refractory a number of myeloma who’ve obtained one to a few prior strains of remedy
• Together with bortezomib and dexamethasone in sufferers who’ve obtained at the least one prior remedy
• As monotherapy in sufferers who’ve obtained at the least three prior strains of remedy together with a proteasome inhibitor (PI) and an immunomodulatory agent or who’re double-refractory to a PI and an immunomodulatory agent

CONTRAINDICATIONS

DARZALEX ^® is contraindicated in sufferers with a historical past of extreme hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of the parts of the formulation.

WARNINGS AND PRECAUTIONS

Infusion-Associated Reactions

DARZALEX ^® could cause extreme and/or critical infusion-related reactions together with anaphylactic reactions. These reactions could be lifethreatening, and deadly outcomes have been reported. In medical trials (monotherapy and mixture: N=2066), infusion-related reactions occurred in 37% of sufferers with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Lower than 1% of sufferers had a Grade 3/4 infusion-related response at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (vary: 0 to 73 hours). Practically all reactions occurred throughout infusion or inside 4 hours of finishing DARZALEX ^®. Extreme reactions have occurred, together with bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular hostile reactions, together with choroidal effusion, acute myopia, and acute angle closure glaucoma. Indicators and signs might embody respiratory signs, similar to nasal congestion, cough, throat irritation, in addition to chills, vomiting, and nausea. Much less widespread indicators and signs had been wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension and blurred imaginative and prescient.

When DARZALEX ^® dosing was interrupted within the setting of ASCT (CASSIOPEIA) for a median of three.75 months (vary: 2.4 to six.9 months), upon re-initiation of DARZALEX ^®, the incidence of infusion-related reactions was 11% for the primary infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX ^® following ASCT had been constant when it comes to signs and severity (Grade 3 or 4:

Pre-medicate sufferers with antihistamines, antipyretics, and corticosteroids. Incessantly monitor sufferers throughout the complete infusion. Interrupt DARZALEX ^® infusion for reactions of any severity and institute medical administration as wanted. Completely discontinue DARZALEX ^® remedy if an anaphylactic response or life-threatening (Grade 4) response happens and institute applicable emergency care. For sufferers with Grade 1, 2, or 3 reactions, scale back the infusion charge when re-starting the infusion.

To cut back the danger of delayed infusion-related reactions, administer oral corticosteroids to all sufferers following DARZALEX ^® infusions. Sufferers with a historical past of power obstructive pulmonary illness might require further post-infusion medicines to handle respiratory issues. Contemplate prescribing short- and long-acting bronchodilators and inhaled corticosteroids for sufferers with power obstructive pulmonary illness.

Ocular hostile reactions, together with acute myopia and narrowing of the anterior chamber angle resulting from ciliochoroidal effusions with potential for elevated intraocular stress or glaucoma, have occurred with DARZALEX infusion. If ocular signs happen, interrupt DARZALEX infusion and search rapid ophthalmologic analysis previous to restarting DARZALEX.

Interference With Serological Testing

Daratumumab binds to CD38 on purple blood cells (RBCs) and leads to a constructive oblique antiglobulin check (oblique Coombs check). Daratumumab-mediated constructive oblique antiglobulin check might persist for up to six months after the final daratumumab infusion. Daratumumab certain to RBCs masks detection of antibodies to minor antigens within the affected person’s serum. The willpower of a affected person’s ABO and Rh blood kind isn’t impacted. Notify blood transfusion facilities of this interference with serological testing and inform blood banks {that a} affected person has obtained DARZALEX ^®. Kind and display sufferers previous to beginning DARZALEX ^®.

Neutropenia and Thrombocytopenia

DARZALEX ^® might enhance neutropenia and thrombocytopenia induced by background remedy. Monitor full blood cell counts periodically throughout therapy in keeping with producer’s prescribing info for background therapies. Monitor sufferers with neutropenia for indicators of an infection. Contemplate withholding DARZALEX ^® till restoration of neutrophils or for restoration of platelets.

Interference With Dedication of Full Response

Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that may be detected on each the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the medical monitoring of endogenous M-protein. This interference can impression the willpower of full response and of illness development in some sufferers with IgG kappa myeloma protein.

Embryo-Fetal Toxicity

Primarily based on the mechanism of motion, DARZALEX ^® could cause fetal hurt when administered to a pregnant lady. DARZALEX ^® might trigger depletion of fetal immune cells and decreased bone density. Advise pregnant ladies of the potential threat to a fetus. Advise females with reproductive potential to make use of efficient contraception throughout therapy with DARZALEX ^® and for 3 months after the final dose.

The mix of DARZALEX ^® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant ladies as a result of lenalidomide, pomalidomide, and thalidomide might trigger start defects and dying of the unborn little one. Confer with the lenalidomide, pomalidomide, or thalidomide prescribing info on use throughout being pregnant.

ADVERSE REACTIONS

Essentially the most continuously reported hostile reactions (incidence ‰¥20%) had been: higher respiratory an infection, neutropenia, infusionrelated reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most typical hematologic laboratory abnormalities ( ‰¥40%) with DARZALEX ^® are: neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia.

Please click on right here to see the complete Prescribing Data.

About Johnson & Johnson
At Johnson & Johnson, we consider well being is the whole lot. Our energy in healthcare innovation empowers us to construct a world the place advanced illnesses are prevented, handled, and cured, the place remedies are smarter and fewer invasive, and options are private. By means of our experience in Progressive Medication and MedTech, we’re uniquely positioned to innovate throughout the complete spectrum of healthcare options at the moment to ship the breakthroughs of tomorrow, and profoundly impression well being for humanity. Study extra at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Observe us at @JanssenUS and @JNJInnovMed. Janssen Analysis & Growth, LLC and Janssen Biotech, Inc., and Janssen World Providers, LLC are Johnson & Johnson firms.

Cautions Regarding Ahead-Trying Statements

This press release incorporates “forward-looking statements” as outlined within the Personal Securities Litigation Reform Act of 1995 concerning product improvement and the potential advantages and therapy impression of DARZALEX FASPRO ^® (daratumumab and hyaluronidase-fihj). The reader is cautioned to not depend on these forward-looking statements. These statements are based mostly on present expectations of future occasions. If underlying assumptions show inaccurate or recognized or unknown dangers or uncertainties materialize, precise outcomes may differ materially from the expectations and projections of Janssen Analysis & Growth, LLC, Janssen Biotech, Inc., Janssen World Providers, LLC and/or Johnson & Johnson. Dangers and uncertainties embody, however usually are not restricted to: challenges and uncertainties inherent in product research and improvement, together with the uncertainty of medical success and of acquiring regulatory approvals; uncertainty of business success; manufacturing difficulties and delays; competitors, together with technological advances, new merchandise and patents attained by opponents; challenges to patents; product efficacy or security issues leading to product recollects or regulatory motion; modifications in habits and spending patterns of purchasers of well being care services; modifications to relevant legal guidelines and laws, together with international well being care reforms; and traits towards well being care value containment. An additional listing and descriptions of those dangers, uncertainties and different elements could be present in Johnson & Johnson’s Annual Report on Type 10-Ok for the fiscal 12 months ended December 31, 2023, together with within the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Experiences on Type 10-Q and different filings with the Securities and Trade Fee. Copies of those filings can be found on-line at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Analysis & Growth, LLC, Janssen Biotech, Inc., Janssen World Providers, LLC, nor Johnson & Johnson undertake to replace any forward-looking assertion because of new info or future occasions or developments.

Dr. Meletios A. Dimopoulos, Nationwide and Kapodistrian College of Athens Faculty of Medication, has supplied consulting, advisory, and talking providers to Johnson & Johnson; he has not been paid for any media work.

¹Dimopoulos, M. et al. Part 3 Randomized Examine of Daratumumab Monotherapy Versus Energetic Monitoring in Sufferers with Excessive-risk Smoldering A number of Myeloma: Main Outcomes of the AQUILA Examine. ASH 2024. December 8, 2024.
²Rajkumar SV. A number of Myeloma: 2020 Replace on Analysis, Danger-Stratification and Administration. Am J Hematol. 2020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178
³Nationwide Most cancers Institute. Plasma Cell Neoplasms. Accessed August 2024. Obtainable at: https://www.most cancers.gov/sorts/myeloma/affected person/myeloma-treatment-pdq
⁴A number of Myeloma. Metropolis of Hope, 2022. A number of Myeloma: Causes, Signs & Therapies. Accessed August 2024. Obtainable at: https://www.cancercenter.com/cancer-types/multiple-myeloma
⁵American Most cancers Society. Myeloma Most cancers Statistics. Accessed August 2024. Obtainable at: https://cancerstatisticscenter.most cancers.org/sorts/myeloma
⁶American Most cancers Society. What’s A number of Myeloma? Accessed August 2024. Obtainable at: https://www.most cancers.org/most cancers/multiple-myeloma/about/what-is-multiple-myeloma.html
⁷American Most cancers Society. A number of Myeloma Early Detection, Analysis, and Staging. Accessed August 2024. Obtainable at: https://www.most cancers.org/most cancers/sorts/multiple-myeloma/detection-diagnosis-staging/detection.html